Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD71 Centyrin–IFIH1 siRNA conjugate
- Development stage
- Preclinical
- Lead developer
- Aro Biotherapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
CD71 Centyrin–IFIH1 siRNA conjugate is a preclinical-stage investigational biologic-oligonucleotide conjugate developed by Aro Biotherapeutics for the treatment of Type 1 Diabetes (T1D). The drug consists of a CD71-targeting Centyrin protein (a small ~10 kDa engineered fibronectin type III domain protein) conjugated to a short-interfering RNA (siRNA) payload that targets IFIH1 mRNA, which encodes the intracellular innate immune sensor protein MDA5. By targeting CD71 (transferrin receptor), the conjugate achieves cell-specific delivery to immune cells and pancreatic cells, enabling extrahepatic delivery of the siRNA. In preclinical studies, the conjugate demonstrated efficient uptake and robust knockdown of IFIH1 in primary human dendritic cells, attenuating Type 1 interferon production. In a Non-Obese Diabetic (NOD) mouse model of T1D, it reduced blood glucose levels, delayed disease onset, and improved survival.
- Other names
- CD71 Centyrin-IFIH1 siRNA conjugateCD-71 Centyrin-IFIH1 siRNA conjugateCD 71 Centyrin-IFIH1 siRNA conjugateCentyrin-IFIH1 siRNA conjugateCentyrin-IFIH-1 siRNA conjugateCentyrin-IFIH 1 siRNA conjugate
02
Targets
AGO2 (Argonaute RISC catalytic component 2)IFIH1 (MDA5)
Beyond the preview
Go deeper on CD71 Centyrin–IFIH1 siRNA conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD71 Centyrin–IFIH1 siRNA conjugate.